Physician profile

Zane Zimmerman

Family Medicine · Napoleon, OH

NPI 1750367249

$612.13

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$364.76

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $172.32 2021-2023 Vraylar
Novo Nordisk INC $105.88 2021-2024 Rybelsus, Ozempic
Sanofi-Aventis U.S. LLC $104.29 2019
Astrazeneca Pharmaceuticals LP $90.41 2021-2024 Breztri, Farxiga
Boehringer Ingelheim Pharmaceuticals, INC. $47.42 2023 Jardiance
Amgen INC. $36.26 2021-2023 Otezla, Repatha
Pfizer INC. $24.70 2021
Janssen Pharmaceuticals, INC $17.77 2023 Xarelto
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $13.08 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Zane Zimmerman

$612.13

in general payments reported 2019-2025

Years
2019-2024
Top company
Abbvie INC.

https://glasscript.com/doctor/1238521/zane-zimmerman

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.